This study is testing new treatments for a type of liver cancer called **Hepatocellular Carcinoma (HCC)**, which cannot be removed by surgery or has spread to other parts of the body. The study is in **Phase 2b**, meaning it is checking how well the new treatment works and if it's safe. It involves two parts: one to test safety and another to compare treatments. The new treatment includes drugs called **visugromab**, **nivolumab**, and **lenvatinib**, compared against **placebos** (inactive substances) with lenvatinib. **Eligibility**: Participants must have this type of liver cancer, be over 18, and have already tried one treatment that included an anti-PD-(L)1 compound without success. They must have good liver function and a life expectancy of at least 3 months. **Key Points**: - Participants will be randomly placed into one of two treatment groups. - The study requires regular visits for treatment and monitoring. - There may be risks involved, and prior health conditions could affect eligibility. This trial is for people who have limited treatment options and meet specific health criteria.